Ladenburg Initiates Genome Therapeutics with Strong Buy

Analyst Albert Rauch believes Genome is well on its way to become a major drug discovery company

Ladenburg Thalmann initiated investment coverage of Genome Therapeutics (GENE ) with a strong buy recommendation.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.